Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update Nov 21, 2022 06:30PM
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update Nov 21, 2022 06:30PM
Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update Aug 16, 2022 04:15PM
Aridis Pharmaceuticals Inc. (ARDS) Announces Antibody Cocktail AR-701 Is Protective in Non-Human Primates Aug 10, 2022 08:31AM
Aridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primates Aug 10, 2022 08:30AM


Mar 31, 2022 06:04PM Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update
Feb 17, 2022 06:45AM Aridis Pharmaceuticals Inc. (ARDS) Reports its Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals
Feb 17, 2022 06:45AM Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals
Jan 27, 2022 07:22AM Aridis Pharmaceuticals Inc. (ARDS) Shares Spiking Higher on Major Volume on News of Grant from Gates Foundation
Jan 27, 2022 06:45AM Aridis Pharmaceuticals Inc. (ARDS) Announces Grant from Gates Foundation to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission
Nov 10, 2021 08:00AM Aridis Pharmaceuticals Announces Third Quarter 2021 Results
Aug 12, 2021 09:00AM Aridis Pharmaceuticals Announces Second Quarter 2021 Results